peripheral T-cell lymphoma
Haematology · 2015–2017
4decisions
2medicines
3carried consumer input
3individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pralatrexate Treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) following first-line chemotherapy. | Jul 2017 | Not recommended | input received Rare Cancer Australia · Peter MacCallum Institute · PTCL Australia · Peter MacCallum Cancer Institute |
| pralatrexate Treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) in adult patients who have progressed after at least one prior therapy. | Nov 2017 | Recommended with restriction | 1 individuals |
| romidepsin Relapsed or chemotherapy refractory peripheral T-cell lymphoma in patients who have received and failed prior systemic therapy and are not candidates for a… | Nov 2016 | Not recommended | 2 individuals Rare Cancers Australia |
| pralatrexate Treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) in adults who have progressed after at least one prior therapy. | Nov 2015 | Not recommended | none received |
Who spoke
Rare Cancer Australia · Peter MacCallum Institute · PTCL Australia · Peter MacCallum Cancer Institute · Rare Cancers Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.